Evolution or Overkill?: Rethinking EU-GMP Requirements in Cannabis Operations

As Europe's medical cannabis market matures, a critical debate has emerged around EU-GMP certification requirements for cultivators. What are the evolving dynamics between GACP cultivation and EU-GMP processing? In a market which appears to be converging quickly, are traditional pharmaceutical manufacturing standards truly necessary for cannabis biomass production?

This panel will discuss emerging business models that separate cultivation and processing certifications, analyzing the financial and operational implications of this shift. Drawing from recent market developments and case studies, speakers will explore how this 'Cannabis 2.0' approach could reshape industry investment, market entry strategies, and supply chain relationships.